CN115443290A - C5ar1的抗体分子及其用途 - Google Patents

C5ar1的抗体分子及其用途 Download PDF

Info

Publication number
CN115443290A
CN115443290A CN202180020518.XA CN202180020518A CN115443290A CN 115443290 A CN115443290 A CN 115443290A CN 202180020518 A CN202180020518 A CN 202180020518A CN 115443290 A CN115443290 A CN 115443290A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
antibody molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020518.XA
Other languages
English (en)
Chinese (zh)
Inventor
K.维斯瓦纳坦
B.布思
B.拉马克里什南
A.沃拉科特
G.巴布科克
Z.施赖弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CN115443290A publication Critical patent/CN115443290A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180020518.XA 2020-01-13 2021-01-13 C5ar1的抗体分子及其用途 Pending CN115443290A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062960544P 2020-01-13 2020-01-13
US62/960,544 2020-01-13
PCT/US2021/013284 WO2021146320A1 (en) 2020-01-13 2021-01-13 Antibody molecules to c5ar1 and uses thereof

Publications (1)

Publication Number Publication Date
CN115443290A true CN115443290A (zh) 2022-12-06

Family

ID=74554227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020518.XA Pending CN115443290A (zh) 2020-01-13 2021-01-13 C5ar1的抗体分子及其用途

Country Status (13)

Country Link
US (3) US11773179B2 (enExample)
EP (1) EP4090680A1 (enExample)
JP (1) JP2023510844A (enExample)
KR (1) KR20220160542A (enExample)
CN (1) CN115443290A (enExample)
AU (1) AU2021207627A1 (enExample)
BR (1) BR112022013780A2 (enExample)
CA (1) CA3166505A1 (enExample)
IL (1) IL294661A (enExample)
MX (1) MX2022008659A (enExample)
TW (1) TWI869528B (enExample)
WO (1) WO2021146320A1 (enExample)
ZA (1) ZA202208280B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002221A1 (en) * 2023-06-27 2025-01-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Multi-specific antibodies comprising antigen-binding domains specifically recognizing c5ar1 and gm-csfr alpha

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN118829654A (zh) * 2021-12-29 2024-10-22 舒泰神(加州)生物科技有限公司 特异性识别C5aR1的抗体及其应用
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用
CN119431573B (zh) * 2024-12-03 2025-08-22 江苏华创誉通医学检验有限公司 一种atg16l1单克隆抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234118A1 (en) * 2017-06-23 2018-12-27 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
CN110072887A (zh) * 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2004082568A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005050199A1 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein- coupled receptor 77 (gpr77)
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20100166741A1 (en) 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
ES2570153T3 (es) 2006-08-22 2016-05-17 Novo Nordisk As Anticuerpos anti-C5aR con propiedades mejoradas
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2009005651A2 (en) 2007-06-29 2009-01-08 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
US8940299B2 (en) 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
US20180256646A1 (en) 2008-03-06 2018-09-13 Case Western Reserve University Compositions and methods for modulating toll like receptor signal
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
US11130801B2 (en) 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
KR102332303B1 (ko) 2013-05-31 2021-11-26 자임워크스 인코포레이티드 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
CN106957366B (zh) 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
KR20190057083A (ko) 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
FR3058159B1 (fr) 2016-10-28 2022-02-25 Lab Francais Du Fractionnement Variants de polypeptide fc presentant une demi-vie augmentee
EP3576793A4 (en) 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING
CN113603780B (zh) 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3120566C (en) 2017-04-07 2023-12-12 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
US20210070860A1 (en) 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
US20200376135A1 (en) 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7617012B2 (ja) 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
US20220306735A1 (en) 2019-08-30 2022-09-29 University Of Kansas Compositions including igg fc mutations and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2021180063A1 (en) 2020-03-09 2021-09-16 I-Mab Biopharma Co., Ltd. Methods for detecting and quantifying biological modifications in antibodies
PH12022552556A1 (en) 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
CA3173944A1 (en) * 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2023081160A1 (en) 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072887A (zh) * 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用
WO2018234118A1 (en) * 2017-06-23 2018-12-27 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAURAV MEHTA等: "A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA", THE JOURNAL OF IMMUNOLOGY, vol. 194, no. 11, 1 June 2015 (2015-06-01), pages 5446, XP055603503, DOI: 10.4049/jimmunol.1403012 *
柯少迎;苏子剑;叶晓楠;翟军伟;张剑华;刘小瑜;王聪仁;潘群雄;: "CD88在胃癌组织中的表达及其对细胞侵袭能力的影响", 中国肿瘤外科杂志, no. 03, 20 June 2016 (2016-06-20), pages 30 - 33 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002221A1 (en) * 2023-06-27 2025-01-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Multi-specific antibodies comprising antigen-binding domains specifically recognizing c5ar1 and gm-csfr alpha

Also Published As

Publication number Publication date
WO2021146320A1 (en) 2021-07-22
TW202140553A (zh) 2021-11-01
KR20220160542A (ko) 2022-12-06
US12415865B2 (en) 2025-09-16
WO2021146320A9 (en) 2021-11-18
ZA202208280B (en) 2025-12-17
BR112022013780A2 (pt) 2022-10-11
US11773179B2 (en) 2023-10-03
US20220089764A1 (en) 2022-03-24
CA3166505A1 (en) 2021-07-22
IL294661A (en) 2022-09-01
TWI869528B (zh) 2025-01-11
JP2023510844A (ja) 2023-03-15
MX2022008659A (es) 2022-11-10
US20240076398A1 (en) 2024-03-07
WO2021146320A8 (en) 2022-07-28
AU2021207627A1 (en) 2022-08-04
EP4090680A1 (en) 2022-11-23
US12187807B2 (en) 2025-01-07
US20240150488A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
CN109089419B (zh) April的抗体分子及其应用
TWI869528B (zh) C5ar1抗體分子及其用途
CN103596982B (zh) 治疗性抗体
CN102421802B (zh) 人源化的axl抗体
WO2021180205A1 (zh) Pvrig结合蛋白及其医药用途
CN108235685A (zh) Pd-1拮抗剂与egfr抑制剂的组合
JP2012506695A (ja) 改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
CN119730874A (zh) 针对april的抗体分子及其用途
WO2024175030A1 (zh) 抗Nectin-4抗体和包含其的多特异性抗体
CN114057876B (zh) Cd47抗体及其应用
TW201110982A (en) Osteopontin antibodies
TW202216195A (zh) April抗體分子及其用途
CN116670168A (zh) 针对april的抗体分子及其用途
HK40085179A (en) Antibody molecules to c5ar1 and uses thereof
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
EA049546B1 (ru) Молекулы антитела к c5ar1 и их способы применения
RU2793755C2 (ru) Молекулы антител против april и их применения
HK40110880A (zh) April的抗体分子及其应用
HK40114871A (zh) April的抗体分子及其应用
WO2026072909A2 (en) Flt1 binding proteins and methods of use
HK40071904A (en) Cd47 antibody and the use thereof
HK40093621A (zh) 针对april的抗体分子及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085179

Country of ref document: HK